Candel Therapeutics
CADL
84 hedge funds and large institutions have $134M invested in Candel Therapeutics in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 10 closing their positions.
249% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $594K
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
15% more capital invested
Capital invested by funds: $116M → $134M (+$17.9M)
4% more funds holding
Funds holding: 81 → 84 (+3)
1.76% more ownership
Funds ownership: 41.29% → 43.05% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.59M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.67M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$557K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$440K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$703K |
| 2 |
Millennium Management
New York
|
-$697K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$630K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$530K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$465K |
CADL Hedge Fund Activity: Q4 2025 in Review
84 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q4 2025, worth a combined $134M — up 15% from $116M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CADL positions and 10 closed out — a net gain of 3 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $2.59M. The largest seller was Wellington Management Group, exiting entirely with an estimated $703K sold.
- 84 institutional investors held Candel Therapeutics (CADL) as of Q4 2025, up from 81 in Q3 2025.
- Funds reported $134M of Candel Therapeutics stock for Q4 2025, up 15% quarter-over-quarter.
- 13 funds opened new Candel Therapeutics positions in Q4 2025 and 10 closed out, a net change of +3 holders.
- The largest Candel Therapeutics buyer in Q4 2025 was BlackRock, an estimated $2.59M added.
- The largest Candel Therapeutics seller in Q4 2025 was Wellington Management Group, an estimated $703K sold.
Based on aggregated 13F filings for Q4 2025.